|Target disease||Glaucoma / Ocular hypertension|
|Development stage||Phase II trial in Japan|
|License out to||Wakamoto Company, Ltd.|
|Overview||The drug has been confirmed by animal tests, etc. to have strong ocular hypotensive effect and neuroprotective action, and is considered to have a new mode of action.
It is a development product optimized based on a seed compound of our compound library. Through the Drug Western method, the target protein has been identified as a heat shock protein Hsp90. We made a presentation of the target protein at ARVO (*) held in May 2013. A glaucoma drug binding to Hsp90 will be the first in the world.
In July 2018 phase II clinical study was completed.
*ARVO: The Association for Research in Vision and Ophthalmology 2012
One of the largest international congresses in the area of ophthalmology
|2013||Mar.||Licensed rights in Japan to Wakamoto Co., Ltd.|
|Dec.||Initiated non-clinical studies|
|2016||Mar.||Completed non-clinical studies|
|Mar.||Initiated phase I trial in Japan|
|2017||Mar.||Completed phase I trial in Japan|
|Aug.||Initiated phase II trial in Japan|
|2018||Jul.||Completed phase II trial in Japan|